Its possible to reduce the risks by eating enough protein and engaging in strength-building exercises, such as weight lifting
8, 2023, the FDA approved Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors
These modifications can lead to mutations, genomic instability, and if not adequately repaired, contribute to carcinogenesis and other genetic disorders [39]
Wird nur das Symptom behandelt, bleibt die zugrunde liegende Problematik bestehen
In animal models of neurodegenerative diseases, it has been demonstrated that administration of GLP-1RAs can result in the improvement of mitochondrial stability
On side effects: GI events were somewhat higher in the tirzepatide arms at the highest doses, consistent with a stronger gastric-emptying effect from the dual GIP and GLP-1 mechanism